{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:28:05Z","timestamp":1791300485385,"version":"4.1.0"},"reference-count":159,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","bprclinrheum.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Rheumatology"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.berh.2016.04.007","type":"journal-article","created":{"date-parts":[[2016,5,27]],"date-time":"2016-05-27T21:41:50Z","timestamp":1464385310000},"page":"149-168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"title":["Idiopathic inflammatory myositis"],"prefix":"10.1016","volume":"30","author":[{"given":"Joanna","family":"Tieu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid E.","family":"Lundberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidya","family":"Limaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.berh.2016.04.007_bib1","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/BOR.0b013e328313bff4","article-title":"Newly identified autoantibodies: relationship to idiopathic inflammatory myopathy subsets and pathogenesis","volume":"20","author":"Gunawardena","year":"2008","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2016.04.007_bib2","doi-asserted-by":"crossref","first-page":"116S","DOI":"10.1111\/1523-1747.ep12356607","article-title":"Humoral immunity in polymyositis\/dermatomyositis","volume":"100","author":"Targoff","year":"1993","journal-title":"J\u00a0Invest Dermatol"},{"issue":"3","key":"10.1016\/j.berh.2016.04.007_bib3","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/08916930600622645","article-title":"Clinical implications of autoantibody screening in patients with autoimmune myositis","volume":"39","author":"Ghirardello","year":"2006","journal-title":"Autoimmunity"},{"issue":"4","key":"10.1016\/j.berh.2016.04.007_bib4","doi-asserted-by":"crossref","first-page":"R78","DOI":"10.1186\/ar2276","article-title":"Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes","volume":"9","author":"Koenig","year":"2007","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.berh.2016.04.007_bib5","first-page":"86","article-title":"The clinical features of dermatomyositis in a South Australian population","volume":"10","author":"Limaye","year":"2007","journal-title":"Int J Rheum Dis"},{"issue":"4","key":"10.1016\/j.berh.2016.04.007_bib6","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/01.md.0000173991.74008.b0","article-title":"Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients","volume":"84","author":"Troyanov","year":"2005","journal-title":"Medicine"},{"issue":"6","key":"10.1016\/j.berh.2016.04.007_bib7","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/00005792-199111000-00002","article-title":"A\u00a0new approach to the classification of idiopathic inflammatory myopathy: myositis specific autoantibodies define useful homogeneous patient groups","volume":"70","author":"Love","year":"1991","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"10.1016\/j.berh.2016.04.007_bib8","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1093\/rheumatology\/kep248","article-title":"HLA-DPB1 associations differ between DRB1*03 positive anti-Jo-1 and anti-PM-Scl antibody positive idiopathic inflammatory myopathy","volume":"48","author":"Chinoy","year":"2009","journal-title":"Rheumatology"},{"issue":"9","key":"10.1016\/j.berh.2016.04.007_bib9","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/art.1780390910","article-title":"Interrelationship of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis","volume":"39","author":"Arnett","year":"1996","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.berh.2016.04.007_bib10","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s00296-010-1637-5","article-title":"A\u00a0three way interplay of DR4, autoantibodies and synovitis in biopsy-proven idiopathic inflammatory myositis","volume":"32","author":"Limaye","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.berh.2016.04.007_bib11","series-title":"Autoantibodies in myositis","author":"Bernstein","year":"1993"},{"issue":"4","key":"10.1016\/j.berh.2016.04.007_bib12","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/art.22506","article-title":"Clinical and immunogenetic features of patients with autoantibodies to asparaginyl-transfer RNA synthetase","volume":"56","author":"Hirakata","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.berh.2016.04.007_bib13","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/art.21883","article-title":"Unusually high frequency of autoantibodies to PL-7 associated with milder muscle disease in Japanese patients with polymyositis\/dermatomyositis","volume":"54","author":"Yamasaki","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.berh.2016.04.007_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060442","article-title":"Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome","volume":"8","author":"Hamaguchi","year":"2013","journal-title":"Plos One"},{"issue":"1","key":"10.1016\/j.berh.2016.04.007_bib15","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/annrheumdis-2012-201800","article-title":"Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients","volume":"73","author":"Aggarwal","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.berh.2016.04.007_bib16","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/rheumatology\/keu404","article-title":"Seronegative polyarthritis revealing antisynthetase syndrome: a multicentre study of 40 patients","volume":"54","author":"Lefevre","year":"2015","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.berh.2016.04.007_bib17","first-page":"363","article-title":"Dermatomyositis-specific antibodies","volume":"74","author":"Bodoki","year":"2015","journal-title":"Z\u00a0Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2016.04.007_bib18","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0092-8674(00)81758-4","article-title":"The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities","volume":"95","author":"Zhang","year":"1998","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.berh.2016.04.007_bib19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s13317-014-0060-4","article-title":"Myositis autoantibodies and clinical phenotypes","volume":"5","author":"Ghirardello","year":"2014","journal-title":"Auto Immun Highlights"},{"key":"10.1016\/j.berh.2016.04.007_bib20","first-page":"1","article-title":"Cutaneous manifestations in dermatomyositis: key clinical and serological features- a comprehensive review","author":"Muro","year":"2015","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"10.1016\/j.berh.2016.04.007_bib21","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/08916930400022681","article-title":"Anti-Mi-2 antibodies","volume":"38","author":"Ghirardello","year":"2005","journal-title":"Autoimmunity"},{"issue":"7","key":"10.1016\/j.berh.2016.04.007_bib22","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/art.24621","article-title":"RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease","volume":"60","author":"Sato","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.berh.2016.04.007_bib23","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/rheumatology\/kep375","article-title":"The RIG-I-like receptor IFIH1\/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody","volume":"49","author":"Nakashima","year":"2010","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.berh.2016.04.007_bib24","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/art.21023","article-title":"Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis","volume":"52","author":"Sato","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.berh.2016.04.007_bib25","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1002\/acr.21728","article-title":"Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody","volume":"64","author":"Cao","year":"2012","journal-title":"Arthritis Care Res"},{"issue":"8","key":"10.1016\/j.berh.2016.04.007_bib26","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/acr.21992","article-title":"Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum","volume":"65","author":"Hall","year":"2013","journal-title":"Arthritis Care Res"},{"issue":"9","key":"10.1016\/j.berh.2016.04.007_bib27","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/rheumatology\/keq153","article-title":"Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis","volume":"49","author":"Hoshino","year":"2010","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.berh.2016.04.007_bib28","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/acr.22728","article-title":"Anti-MDA5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis","volume":"68","author":"Moghadam-Kia","year":"2016","journal-title":"Arthritis Care Res"},{"issue":"11","key":"10.1016\/j.berh.2016.04.007_bib29","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1002\/art.22164","article-title":"A\u00a0novel autoantibody to a 155-kd protein is associated with dermatomyositis","volume":"54","author":"Targoff","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.berh.2016.04.007_bib30","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/rheumatology\/kel161","article-title":"Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy","volume":"46","author":"Kaji","year":"2007","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.berh.2016.04.007_bib31","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/art.33379","article-title":"Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis","volume":"64","author":"Trallero-Araguas","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.berh.2016.04.007_bib32","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/rheumatology\/ket383","article-title":"Anti-transcription intermediary factor 1-gamma autoantibody ELISA development and validation","volume":"53","author":"Aggarwal","year":"2014","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.berh.2016.04.007_bib33","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/annrheumdis-2011-200697","article-title":"Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy","volume":"71","author":"Ichimura","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.berh.2016.04.007_bib34","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1002\/art.38093","article-title":"Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1\u03b3","volume":"65","author":"Fiorentino","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.berh.2016.04.007_bib35","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jim.2012.07.019","article-title":"Anti-SAE antibodies in autoimmune myositis identification by unlabelled protein immunoprecipitation in an Italian patient cohort","volume":"384","author":"Tarricone","year":"2012","journal-title":"J\u00a0Immunol Methods"},{"issue":"10","key":"10.1016\/j.berh.2016.04.007_bib36","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1136\/ard.2008.097162","article-title":"Clinical and HLA-class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK adult-onset Caucasian myositis","volume":"68","author":"Betteridge","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"38","key":"10.1016\/j.berh.2016.04.007_bib37","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1365-2990.2012.01302.x","article-title":"Immune-mediated necrotizing myopathies \u2013 a heterogeneous group of diseases with specific myopathological features","volume":"2012","author":"Stenzel","year":"2012","journal-title":"Neuropathol App Neurobiol"},{"key":"10.1016\/j.berh.2016.04.007_bib38","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/art.11484","article-title":"Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy","volume":"50","author":"Kao","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.berh.2016.04.007_bib39","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1136\/ard.60.2.116","article-title":"Autoantibody profiles in the sera of European patients with myositis","volume":"60","author":"Brouwer","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2016.04.007_bib40","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1002\/art.1780330908","article-title":"Antibody to signal recognition particle in polymyositis","volume":"33","author":"Targoff","year":"1990","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.berh.2016.04.007_bib41","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/jnnp.73.4.420","article-title":"Myopathy with antibodies to the signal recognition particle: clinical and pathological features","volume":"73","author":"Miller","year":"2002","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.berh.2016.04.007_bib42","first-page":"69","article-title":"Clinical and serological characteristics of 125 Dutch myositis patients: myositis specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies","volume":"249","author":"Hengstman","year":"2002","journal-title":"J\u00a0Neurol"},{"issue":"7","key":"10.1016\/j.berh.2016.04.007_bib43","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/1529-0131(199707)40:7<1257::AID-ART10>3.0.CO;2-R","article-title":"Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies","volume":"40","author":"Hausmanowa-Petrusewicz","year":"1997","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.berh.2016.04.007_bib44","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1136\/ard.2006.052191","article-title":"Anti-signal recognition particle autoantibodies: marker of necrotising myopathy","volume":"65","author":"Hengstman","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"61","key":"10.1016\/j.berh.2016.04.007_bib45","article-title":"Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients","volume":"10","author":"Suzuki","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.berh.2016.04.007_bib46","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/art.27572","article-title":"A\u00a0novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy","volume":"62","author":"Christopher-Stine","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.berh.2016.04.007_bib47","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","article-title":"Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy","volume":"63","author":"Mammen","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.berh.2016.04.007_bib48","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/acr.21671","article-title":"Increased frequency of DRB1*11:01 in anti-hydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy","volume":"64","author":"Mammen","year":"2012","journal-title":"Arthritis Care Res"},{"issue":"2","key":"10.1016\/j.berh.2016.04.007_bib49","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/mus.24541","article-title":"Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase in patients with immune-mediated myositis and necrotizing myopathy","volume":"52","author":"Limaye","year":"2015","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.berh.2016.04.007_bib50","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/mus.24642","article-title":"The composition of cellular infiltrates in anti-HMG-CoA reductase-associated myopathy","volume":"52","author":"Chung","year":"2015","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.berh.2016.04.007_bib51","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/acr.20662","article-title":"Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects","volume":"64","author":"Mammen","year":"2012","journal-title":"Arthritis Care Res"},{"issue":"12","key":"10.1016\/j.berh.2016.04.007_bib52","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1002\/art.34673","article-title":"Antibody levels correlate with creatine kinase levels and strength in anti-HMG-CoA reductase-associated autoimmune myopathy","volume":"64","author":"Werner","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.berh.2016.04.007_bib53","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1097\/01.bor.0000434673.85515.89","article-title":"The spectrum of statin myopathy","volume":"25","author":"Mohassel","year":"2013","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"10.1016\/j.berh.2016.04.007_bib54","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ana.23840","article-title":"Cytosolic 5'-nucleotidase 1A autoimmunity in sporadic inclusion body myositis","volume":"73","author":"Larman","year":"2013","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.berh.2016.04.007_bib55","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ana.23822","article-title":"Autoantibodies to cytosolic 5'-nucleotidase 1A in inclusion body myositis","volume":"73","author":"Pluk","year":"2013","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1016\/j.berh.2016.04.007_bib56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020266","article-title":"Autoantibodies against a 43 KDa muscle protein in inclusion body myositis","volume":"6","author":"Salajegheh","year":"2011","journal-title":"Plos One"},{"issue":"4","key":"10.1016\/j.berh.2016.04.007_bib57","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/annrheumdis-2014-206691","article-title":"Disease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases","volume":"75","author":"Herbert","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2016.04.007_bib58","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/acr.22600","article-title":"Cytosolic 5'-Nucleotidase 1A As a target of circulating autoantibodies in autoimmune diseases","volume":"68","author":"Lloyd","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"10.1016\/j.berh.2016.04.007_bib59","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/mus.24989","article-title":"Anti-cN1A antibodies in South Australian patients with inclusion body myositis","volume":"53","author":"Limaye","year":"2016","journal-title":"Muscle Nerve"},{"issue":"12","key":"10.1016\/j.berh.2016.04.007_bib60","doi-asserted-by":"crossref","first-page":"4612","DOI":"10.1172\/JCI81031","article-title":"Development of autoantibodies against muscle-specific FHL1 in severe inflammatory myopathies","volume":"125","author":"Albrecht","year":"2015","journal-title":"J\u00a0Clin Invest"},{"issue":"6","key":"10.1016\/j.berh.2016.04.007_bib61","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1136\/annrheumdis-2015-207509","article-title":"PUF60: a prominent new target of the autoimmune response in dermatomyositis and Sj\u00f6gren's syndrome","volume":"75","author":"Fiorentino","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"23","key":"10.1016\/j.berh.2016.04.007_bib62","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1101\/gad.1603907","article-title":"Human Y5 RNA specializes a Ro ribonucleoprotein for 5S ribosomal RNA quality control","volume":"21","author":"Hogg","year":"2007","journal-title":"Genes Dev"},{"issue":"14","key":"10.1016\/j.berh.2016.04.007_bib63","article-title":"Identification of genes with a correlation between copy number and expression in gastric cancer","volume":"5","author":"Cheng","year":"2012","journal-title":"BMC Med Genomics"},{"issue":"4","key":"10.1016\/j.berh.2016.04.007_bib64","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009983","article-title":"Identification of candidate growth promoting genes in ovarian cancer through integrated copy number and expression analysis","volume":"5","author":"Ramakrishna","year":"2010","journal-title":"Plos One"},{"issue":"1012","key":"10.1016\/j.berh.2016.04.007_bib65","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/pgmj.2009.089656","article-title":"Diagnostic utility of anti-Ro52 detection in systemic autoimmunity","volume":"86","author":"Dugar","year":"2010","journal-title":"Postgrad Med J"},{"issue":"9","key":"10.1016\/j.berh.2016.04.007_bib66","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.autrev.2011.03.004","article-title":"Clinical significance of anti-Ro52 (TRIM 21) antibodies non-associated with anti-SSA 60kDa antibodies: results of a multicentric study","volume":"10","author":"Ghillani","year":"2011","journal-title":"Autoimmun Rev"},{"issue":"7","key":"10.1016\/j.berh.2016.04.007_bib67","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.autrev.2009.02.010","article-title":"Latest update on the Ro\/SS-A autoantibody system","volume":"8","author":"Schulte-Pelkum","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2016.04.007_bib68","first-page":"2012","article-title":"Anti-Ro52 antibodies and interstitial lung disease in connective tissue diseases excluding scleroderma","author":"Ferreira","year":"2012","journal-title":"ISRN Rheumatol"},{"issue":"7","key":"10.1016\/j.berh.2016.04.007_bib69","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.autrev.2007.01.013","article-title":"Novel aspects of autoantibodies to the PM\/Scl complex: clinical, genetic and diagnostic insights","volume":"6","author":"Mahler","year":"2007","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.berh.2016.04.007_bib70","doi-asserted-by":"crossref","first-page":"R22","DOI":"10.1186\/ar2614","article-title":"Antibodies against PM\/Scl-75 and PM\/Scl-100 are independent markers for different subsets of systemic sclerosis patients","volume":"11","author":"Hanke","year":"2009","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.berh.2016.04.007_bib71","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1365-2133.2009.09484.x","article-title":"Long-term outcome of patients with polymyositis\/dermatomyositis and anti-PM-Scl antibody","volume":"162","author":"Marie","year":"2010","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.berh.2016.04.007_bib72","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.revmed.2010.04.004","article-title":"Idiopathic inflammatory myopathies with anti-PM-Scl antibodies: case series and literature review","volume":"31","author":"Marie","year":"2010","journal-title":"Rev Med Interne"},{"issue":"10","key":"10.1016\/j.berh.2016.04.007_bib73","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.autrev.2010.05.020","article-title":"Anti-ku antibodies: clinical, genetic and diagnostic insights","volume":"9","author":"Belizna","year":"2010","journal-title":"Autoimmun Rev"},{"issue":"7","key":"10.1016\/j.berh.2016.04.007_bib74","first-page":"1393","article-title":"Anti-ku antibodies in connective tissue diseases: clinical and serological evaluation of 14 patietns","volume":"29","author":"Franceschini","year":"2002","journal-title":"J\u00a0Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2016.04.007_bib75","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/MD.0b013e31824d9cec","article-title":"Inflammatory myopathies with anti-Ku antibodies: a prognosis dependent on associated lung disease","volume":"91","author":"Rigolet","year":"2012","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.berh.2016.04.007_bib76","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1046\/j.1365-2249.1997.4081308.x","article-title":"Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy","volume":"209","author":"Rutjes","year":"1997","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"10.1016\/j.berh.2016.04.007_bib77","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3109\/14397595.2015.1091155","article-title":"Clinical subsets associated with different anti-aminoacyl transfer RNA synthetase antibodies and their association with coexisting anti-Ro52","volume":"26","author":"Yamasaki","year":"2016","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.berh.2016.04.007_bib78","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJM199111213252107","article-title":"Polymyositis, dermatomyositis, and inclusion body myositis","volume":"325","author":"Dalakas","year":"1991","journal-title":"NEJM"},{"issue":"4","key":"10.1016\/j.berh.2016.04.007_bib79","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.bbadis.2014.05.034","article-title":"Dermatomyositis, polymyositis and immune-mediated necrotising myopathies","volume":"1852","author":"Luo","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.berh.2016.04.007_bib80","series-title":"Structural and molecular basis of skeletal muscle diseases","first-page":"221","article-title":"Polymyositis and dermatomyositis","author":"Hohlfeld","year":"2002"},{"issue":"6","key":"10.1016\/j.berh.2016.04.007_bib81","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/BOR.0b013e32834bab42","article-title":"Acquired immune and inflammatory myopathies: pathologic classification","volume":"23","author":"Pestronk","year":"2011","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2016.04.007_bib82","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","article-title":"119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands","volume":"14","author":"Hoogendijk","year":"2004","journal-title":"Neuromusc Disord"},{"issue":"4 pt 2","key":"10.1016\/j.berh.2016.04.007_bib83","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1016\/j.lpm.2011.01.005","article-title":"Pathophysiology of inflammatory and autoimmune myopathies","volume":"40","author":"Dalakas","year":"2011","journal-title":"Presse Med"},{"key":"10.1016\/j.berh.2016.04.007_bib84","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","article-title":"Polymyositis and dermatomyositis","volume":"362","author":"Dalakas","year":"2003","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.berh.2016.04.007_bib85","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00401-009-0564-6","article-title":"p62\/SQSTM1 is overexpressed and prominently accumulated in inclusions of sporadic inclusion-body myositis muscle fibers, and can help differentiating it from polymyositis and dermatomyositis","volume":"118","author":"Nogalska","year":"2009","journal-title":"Acta Neuropathol"},{"issue":"4","key":"10.1016\/j.berh.2016.04.007_bib86","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-004552","article-title":"A\u00a0retrospective cohort study identifying the principal pathological features useful in the diagnosis of inclusion body myositis","volume":"4","author":"Brady","year":"2014","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.berh.2016.04.007_bib87","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jocn.2014.09.012","article-title":"Inclusion body myositis: a review of clinical and genetic aspects, diagnostic criteria and therapeutic approaches","volume":"22","author":"Mastaglia","year":"2015","journal-title":"J\u00a0Clin Neurosci"},{"issue":"4","key":"10.1016\/j.berh.2016.04.007_bib88","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.nmd.2014.12.010","article-title":"Mitochondtrial pathology in inclusion body myositis","volume":"25","author":"Lindgren","year":"2015","journal-title":"Neuromusc Disord"},{"issue":"12","key":"10.1016\/j.berh.2016.04.007_bib89","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.nmd.2013.08.007","article-title":"188th ENMC international workshop: inclusion body myositis, 2-4 December 2011, Naarden, The Netherlands","volume":"23","author":"Rose","year":"2013","journal-title":"Neuromusc Disord"},{"issue":"3","key":"10.1016\/j.berh.2016.04.007_bib90","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/CND.0b013e31815e5d4a","article-title":"Steroid-responsive myopathy: immune-mediated necrotizing myopathy or polymyositis without inflammation?","volume":"9","author":"Sadeh","year":"2008","journal-title":"J\u00a0Clin Neuromuscul Dis"},{"issue":"4","key":"10.1016\/j.berh.2016.04.007_bib91","first-page":"480","article-title":"Necrotising myopathy, an unusual presentation of a steroid-responsive myopathy","volume":"250","author":"Bronner","year":"2003","journal-title":"J\u00a0Neurol"},{"issue":"1\u20132","key":"10.1016\/j.berh.2016.04.007_bib92","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0165-5728(97)00033-7","article-title":"Pulsed intravenous methylprednisolone therapy for inflammatory myopathies: evaluation of the effect by comparing two consecutive biopsies from the same muscle","volume":"76","author":"Matsubara","year":"1997","journal-title":"J\u00a0Neuroimmunol"},{"issue":"6","key":"10.1016\/j.berh.2016.04.007_bib93","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0167-5699(94)90006-X","article-title":"The immunobiology of muscle","volume":"15","author":"Hohlfeld","year":"1994","journal-title":"Immunol Today"},{"key":"10.1016\/j.berh.2016.04.007_bib94","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1046\/j.1365-2249.1998.00664.x","article-title":"A\u00a0variety of cytokines and immunologically relevant surface molecules are expressed by normal human skeletal muscle cells under proinflammatory stimuli","volume":"113","author":"Nagaraju","year":"1998","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"10.1016\/j.berh.2016.04.007_bib95","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1002\/art.21103","article-title":"Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction","volume":"52","author":"Nagaraju","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.berh.2016.04.007_bib96","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2169\/internalmedicine.33.263","article-title":"Temporal alterations of immunohistochemical findings in polymyositis","volume":"33","author":"Tajima","year":"1994","journal-title":"Intern Med"},{"issue":"3","key":"10.1016\/j.berh.2016.04.007_bib97","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.coph.2010.03.001","article-title":"Inflammatory muscle diseases: a critical review on pathogenesis and therapies","volume":"10","author":"Dalakas","year":"2010","journal-title":"Curr Opin Pharmacol"},{"issue":"6","key":"10.1016\/j.berh.2016.04.007_bib98","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1046\/j.1365-2990.2003.00471.x","article-title":"Class I MHC detection as a diagnostic tool in noninformative muscle biopsies of patients suffering from dermatomyositis (DM)","volume":"29","author":"Civatte","year":"2003","journal-title":"Neuropathol App Neurobiol"},{"issue":"2","key":"10.1016\/j.berh.2016.04.007_bib99","doi-asserted-by":"crossref","first-page":"661","DOI":"10.4049\/jimmunol.149.2.661","article-title":"Human myoblasts as antigen-presenting cells","volume":"149","author":"Goebels","year":"1992","journal-title":"J\u00a0Immunol"},{"issue":"6","key":"10.1016\/j.berh.2016.04.007_bib100","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/PAI.0b013e31827d7f16","article-title":"Major histocompatibility complex class I and II expression in idiopathic inflammatory myopathy","volume":"21","author":"Das","year":"2013","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"12","key":"10.1016\/j.berh.2016.04.007_bib101","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.nmd.2014.06.436","article-title":"An analysis of the sensitivity and specificity of MHC-I and MHC-II immunohistochemical staining in muscle biopsies for the diagnosis of inflammatory myopathies","volume":"24","author":"Rodr\u00edguez Cruz","year":"2014","journal-title":"Neuromusc Disord"},{"issue":"1","key":"10.1016\/j.berh.2016.04.007_bib102","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/jclinpath-2011-200138","article-title":"Validity of internal expression of the major histocompatibility complex class I in the diagnosis of inflammatory myopathies","volume":"65","author":"Salaroli","year":"2012","journal-title":"J\u00a0Clin Path"},{"issue":"Pt 9","key":"10.1016\/j.berh.2016.04.007_bib103","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1093\/brain\/awv192","article-title":"Anti-Jo-1 antibody-positive patients show a characteristic necrotizing perifascicular myositis","volume":"138","author":"Mescam-Mancini","year":"2015","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.berh.2016.04.007_bib104","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1600-0404.2010.01353.x","article-title":"Detection of the membrane attack complex as a diagnostic tool in dermatomyositis","volume":"123","author":"Jain","year":"2011","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"10.1016\/j.berh.2016.04.007_bib105","doi-asserted-by":"crossref","first-page":"513","DOI":"10.4103\/0028-3886.84329","article-title":"Immunohistochemical differentiation of inflammatory myopathies","volume":"59","author":"Panicker","year":"2011","journal-title":"Neurol India"},{"issue":"6","key":"10.1016\/j.berh.2016.04.007_bib106","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3346\/jkms.2009.24.6.1015","article-title":"Differential immunohistological features of inflammatory myopathies and dysferlinopathy","volume":"24","author":"Choi","year":"2009","journal-title":"J\u00a0Korean Med Sci"},{"issue":"3","key":"10.1016\/j.berh.2016.04.007_bib107","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00401-006-0113-5","article-title":"The inflammatory reaction pattern distinguishes primary dysferlinopathies from idiopathic inflammatory myopathies: an important role for the membrane attack complex","volume":"112","author":"Brunn","year":"2006","journal-title":"Acta Neuropathol"},{"issue":"1\u20132","key":"10.1016\/j.berh.2016.04.007_bib108","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0165-5728(03)00255-8","article-title":"Muscle inflammation and MHC class I up-regulation in muscular dystrophy with lack of dysferlin: an immunopathological study","volume":"142","author":"Confalonieri","year":"2003","journal-title":"J\u00a0Neuroimmunol"},{"issue":"7","key":"10.1016\/j.berh.2016.04.007_bib109","first-page":"736","article-title":"Pathogenic considerations in sporadic inclusion-body myositis, a degenerative muscle disease associated with aging and abnormalities of myoproteostasis","volume":"39","author":"Askanas","year":"2012","journal-title":"J\u00a0Neuropathol Exp Neurol"},{"issue":"7","key":"10.1016\/j.berh.2016.04.007_bib110","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/nan.12040","article-title":"Overexpression of autophagic proteins in the skeletal muscle of sporadic inclusion body myositis","volume":"39","author":"Girolamo","year":"2013","journal-title":"Neuropathol App Neurobiol"},{"issue":"2","key":"10.1016\/j.berh.2016.04.007_bib111","doi-asserted-by":"crossref","first-page":"138","DOI":"10.4161\/auto.2.2.2405","article-title":"p62\/SQSTM1: a missing link between protein aggregates and the autophagy machinery","volume":"2","author":"Bj\u00f8rk\u00f8y","year":"2006","journal-title":"Autophagy"},{"issue":"18","key":"10.1016\/j.berh.2016.04.007_bib112","doi-asserted-by":"crossref","first-page":"8055","DOI":"10.1128\/MCB.24.18.8055-8068.2004","article-title":"Sequestosome 1\/p62 is a polyubiquitin chain binding protein involved in ubiquitin proteasome degradation","volume":"24","author":"Seibenhener","year":"2004","journal-title":"Mol Cell Biol"},{"issue":"1","key":"10.1016\/j.berh.2016.04.007_bib113","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/2051-5960-1-29","article-title":"Comparative utility of LC3, p62 and TDP-43 immunohistochemistry in differentiation of inclusion body myositis from polymyositis and related inflammatory myopathies","volume":"1","author":"Hiniker","year":"2013","journal-title":"Acta Neuropathol Commun"},{"issue":"4","key":"10.1016\/j.berh.2016.04.007_bib114","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/ncprheum0760","article-title":"Mechanisms of disease: autoantigens as clues to the pathogenesis of myositis","volume":"4","author":"Suber","year":"2008","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2016.04.007_bib115","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s40478-014-0154-2","article-title":"Myofiber HLA-DR expression is a distinctive biomarker for antisynthetase-associated myopathy","volume":"23","author":"Aouizerate","year":"2014","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.berh.2016.04.007_bib116","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"NEJM"},{"issue":"8","key":"10.1016\/j.berh.2016.04.007_bib117","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.3899\/jrheum.141443","article-title":"The prevalence of individual histopathologic features varies according to autoantibody status in muscle biopsies from patients with dermatomyositis","volume":"42","author":"Pinal-Fernandez","year":"2015","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2016.04.007_bib118","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2010.09.016","article-title":"The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study","volume":"65","author":"Fiorentino","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.berh.2016.04.007_bib119","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1002\/acr.22620","article-title":"Spectrum of muscle histopathologic findings in forty-two scleroderma patients with weakness","volume":"67","author":"Paik","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"8","key":"10.1016\/j.berh.2016.04.007_bib120","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/1756-185X.12592","article-title":"SLE myopathy: a clinicopathological study","volume":"18","author":"Jakati","year":"2015","journal-title":"Int J Rheumatic Dis"},{"key":"10.1016\/j.berh.2016.04.007_bib121","unstructured":"International myosisitis assessment & clinical studies group (IMACS): global approaches to improved treatments and understanding of myositis.: National Institute of Environmental Health Sciences; [cited 2015]. Available from: http:\/\/www.niehs.nih.gov\/research\/resources\/imacs\/index.cfm."},{"issue":"Suppl. 11","key":"10.1016\/j.berh.2016.04.007_bib122","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1002\/acr.20532","volume":"63","author":"Rider","year":"2011","journal-title":"Arthritis Care Res"},{"issue":"7","key":"10.1016\/j.berh.2016.04.007_bib123","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1002\/art.20349","article-title":"International consensus on preliminary definitions of improvement in adult and juvenile myositis","volume":"50","author":"Rider","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.berh.2016.04.007_bib124","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0002-9343(93)90148-I","article-title":"Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy","volume":"94","author":"Joffe","year":"1993","journal-title":"Am J Med"},{"issue":"6","key":"10.1016\/j.berh.2016.04.007_bib125","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.nmd.2010.03.011","article-title":"Oral dexamethasone pulse therapy versus daily prednisolone in sub-acute onset myositis, a randomised controlled trial","volume":"20","author":"Vd","year":"2010","journal-title":"Neuromusc Disord"},{"key":"10.1016\/j.berh.2016.04.007_bib126","unstructured":"J. V. Combined treatment of methotrexate + glucocorticoids versus glucocorticoids alone in patients with polymyositis and dermatomyositis (prometheus). NCT00651040. clinicaltrials.gov2013."},{"issue":"3","key":"10.1016\/j.berh.2016.04.007_bib127","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/ana.10121","article-title":"Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo","volume":"51","author":"Badrising","year":"2002","journal-title":"Ann Neurol"},{"key":"10.1016\/j.berh.2016.04.007_bib128","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2230.2011.04188.x","article-title":"Efficacy of low-dose methotrexate in the treatment of dermatomyositis skin lesions","volume":"37","author":"Hornung","year":"2011","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.berh.2016.04.007_bib129","doi-asserted-by":"crossref","first-page":"365","DOI":"10.7326\/0003-4819-92-3-365","article-title":"Azathioprine with prednisone for polymyositis","volume":"92","author":"Bunch","year":"1980","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.berh.2016.04.007_bib130","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/art.1780240107","article-title":"Prednisone and azathioprine for polymyositis","volume":"24","author":"Bunch","year":"1981","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.berh.2016.04.007_bib131","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1002\/acr.20219","article-title":"Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series","volume":"62","author":"Valiyll","year":"2010","journal-title":"Arthritis Care Res"},{"issue":"3","key":"10.1016\/j.berh.2016.04.007_bib132","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/MD.0000000000000028","article-title":"Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin","volume":"93","author":"Allenbach","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.berh.2016.04.007_bib133","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1136\/ard.61.1.37","article-title":"Cyclosporin A and intravenous immunoglobulin treatment in polymyositis\/dermatomyositis","volume":"61","author":"Danieli","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2016.04.007_bib134","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/030097400750001897","article-title":"Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis","volume":"29","author":"Vencovsky","year":"2000","journal-title":"Scand J Rheumatol"},{"issue":"3","key":"10.1016\/j.berh.2016.04.007_bib135","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/1529-0131(199803)41:3<392::AID-ART3>3.0.CO;2-X","article-title":"Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens","volume":"41","author":"Villalba","year":"1998","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.berh.2016.04.007_bib136","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.berh.2016.04.007_bib137","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133702","article-title":"Efficacy of rituximab in refractory inflammatory myopathies associated with anti-synthetase auto-antibodies: an open-label, phase III trial","volume":"10","author":"Allenbach","year":"2015","journal-title":"PlosOne"},{"key":"10.1016\/j.berh.2016.04.007_bib138","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1093\/rheumatology\/ker305","article-title":"Efficacy and safety of rituximab in the treatment of refractoy inflammatory myopathies in adults: results from the AIR registry","volume":"50","author":"Couderc","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2016.04.007_bib139","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/rheumatology\/ker088","article-title":"Rituximab treatment in patients with refractory inflammatory myopathies","volume":"50","author":"Mahler","year":"2011","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.berh.2016.04.007_bib140","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/art.20849","article-title":"Rituximab in the treatment of dermatomyositis","volume":"52","author":"Levine","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2016.04.007_bib141","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1093\/rheumatology\/keu024","article-title":"Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population","volume":"53","author":"Unger","year":"2014","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.berh.2016.04.007_bib142","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/art.38270","article-title":"Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis","volume":"66","author":"Aggarwal","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2016.04.007_bib143","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1093\/rheumatology\/kep027","article-title":"Poor response of anti-SRP positive idiopathic immune myositis to B-cell depletion [letter]","volume":"48","author":"Whelan","year":"2009","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.berh.2016.04.007_bib144","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.nmd.2006.03.002","article-title":"Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP)","volume":"16","author":"Arlet","year":"2006","journal-title":"Neuromusc Disord"},{"issue":"27","key":"10.1016\/j.berh.2016.04.007_bib145","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A\u00a0controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"NEJM"},{"issue":"3","key":"10.1016\/j.berh.2016.04.007_bib146","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1212\/WNL.48.3.712","article-title":"Treatment of inclusion-body myositis with IVIG: a double-blind, placebo-controlled study","volume":"48","author":"Dalakas","year":"1997","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.berh.2016.04.007_bib147","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1002\/acr.20325","article-title":"Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73 patients","volume":"62","author":"Marie","year":"2010","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2016.04.007_bib148","article-title":"Polymyositis associated with severe interstitial lung disease: remission after three doses of IV immunoglobulin","volume":"139","author":"Blakewell","year":"2011","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.berh.2016.04.007_bib149","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00408-009-9146-6","article-title":"Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis\/dermatomyositis","volume":"187","author":"Suzuki","year":"2009","journal-title":"Lung"},{"key":"10.1016\/j.berh.2016.04.007_bib150","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMc1506163","article-title":"Intravenous immune globulin for statin-triggered autoimmune myopathy","volume":"373","author":"Mammen","year":"2015","journal-title":"NEJM"},{"key":"10.1016\/j.berh.2016.04.007_bib151","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1056\/NEJM199205213262102","article-title":"Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis","volume":"326","author":"Miller","year":"1992","journal-title":"NEJM"},{"issue":"6","key":"10.1016\/j.berh.2016.04.007_bib152","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3899\/jrheum.131145","article-title":"Resistive home exercise in patients with recent-onset polymyositis and dermatomyositis \u2013 a randomized controlled single-blinded study with a 2-year followup","volume":"41","author":"Alexanderson","year":"2014","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2016.04.007_bib153","doi-asserted-by":"crossref","DOI":"10.1002\/art.39624","article-title":"Endurance exercise improves molecular pathways of aerobic metabolism in patients with myositis","author":"Munters","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.berh.2016.04.007_bib154","doi-asserted-by":"crossref","first-page":"R83","DOI":"10.1186\/ar4263","article-title":"Improved exercise performance and increased aerobic capacity after endurance training of patients with stable polymyositis and dermatomyositis","volume":"15","author":"Alemo Munters","year":"2013","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"10.1016\/j.berh.2016.04.007_bib155","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/acr.22068","article-title":"Improvement in health and possible reduction in disease activity using endurance exercise in patients with established polymyositis and dermatomyositis: a multicenter randomized controlled trial with a 1-year open extension followup","volume":"65","author":"Alemo Munters","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"11","key":"10.1016\/j.berh.2016.04.007_bib156","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1136\/ard.2005.045690","article-title":"Long-term outcome in polymyositis and dermatomyositis","volume":"65","author":"Bronner","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.berh.2016.04.007_bib157","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.autrev.2014.08.023","article-title":"Impact of treatment on survival in polymyositis and dermatomyositis. A single-centre long-term follow-up study","volume":"13","author":"Danieli","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2016.04.007_bib158","unstructured":"EuroMyositis: international collaboration research and treatment database for myositis specialists: EuroMyositis; [cited 2015]. Available from: www.euromyositis.eu."},{"key":"10.1016\/j.berh.2016.04.007_bib159","article-title":"Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups","author":"Rothwell","year":"2015","journal-title":"Ann Rheum Dis"}],"container-title":["Best Practice &amp; Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694216300225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694216300225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T01:58:32Z","timestamp":1718589512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694216300225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":159,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S1521694216300225"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2016.04.007","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Idiopathic inflammatory myositis","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2016.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2016 Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}